Liver Fibrosis is a result of all chronic liver diseases. An extended illness from Liver Fibrosis leads to Cirrhosis of liver and finally liver cancer. It’s a serious disease and one of the world’s rising concern. The medical diagnosis of this disease is very painful and involves a risk of hazards such as severe bleeding and also death. The market of Liver Fibrosis has been estimated at $83 billion and it is expected to rise given more and more people are getting affected due to high consumption of alcohol and unhealthy life style. There are lot of drugs under trial and is expected to be launched in the market by 2021. Some of these medicines are also lined up for FDA’s approval.
According to American Liver Foundation (AFL) almost 50% of the American population will be suffering from liver diseases by 2030. Most of the pharamaceutical companies are only in its phase I or phase II of medical trial so there are ample opprotunities for new entrants in this market. The antifibrotic drugs presently available in the market are not good enough remedy as there are lot of side effects. Some of the pharmaceutical companies that are involved in the therapeutic developments are Advinus Therapeutics Ltd., Angion Biomedica Corp., BerGenBio AS, BiOrion Technologies B.V., Celgene Corporation, Digna Biotech, S.L., FibroGen, Inc., Galectin Therapeutics, Inc., Genfit SA, GenKyoTex S.A., Gilead Sciences, Inc., GNI Group Ltd., La Jolla Pharmaceutical Company, LG Life Sciences, Ltd., Nitto Denko Corporation, Pharmaxis Limited, Promedior, Inc., Promethera Biosciences S.A., ProMetic Life Sciences Inc., RXi Pharmaceuticals Corporation, TCM Biotech International Corp, Vascular Biogenics Ltd. and Virobay Inc. Some of the important drugs for the treatment of this disease are ANG-3281, BOT-162, CC-539, DB-036, F-351, GR-MD-02, HepaStem, KW-0 LJPC-201, melittin ND-L02s0201, PXS-5033A, RXI-209, simtuzumab, TCM-808FB, VBY-825 and ohers.